Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein Cholesterol) and Triglyceride Concentrations
Overview
Genetics
Authors
Affiliations
Background: ChREBP (carbohydrate responsive element binding protein) is a transcription factor that responds to sugar consumption. Sugar-sweetened beverage (SSB) consumption and genetic variants in the locus have separately been linked to HDL-C (high-density lipoprotein cholesterol) and triglyceride concentrations. We hypothesized that SSB consumption would modify the association between genetic variants in the locus and dyslipidemia.
Methods: Data from 11 cohorts from the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (N=63 599) and the UK Biobank (N=59 220) were used to quantify associations of SSB consumption, genetic variants, and their interaction on HDL-C and triglyceride concentrations using linear regression models. A total of 1606 single nucleotide polymorphisms within or near were considered. SSB consumption was estimated from validated questionnaires, and participants were grouped by their estimated intake.
Results: In a meta-analysis, rs71556729 was significantly associated with higher HDL-C concentrations only among the highest SSB consumers (β, 2.12 [95% CI, 1.16-3.07] mg/dL per allele; <0.0001), but not significantly among the lowest SSB consumers (=0.81; <0.0001). Similar results were observed for 2 additional variants (rs35709627 and rs71556736). For triglyceride, rs55673514 was positively associated with triglyceride concentrations only among the highest SSB consumers (β, 0.06 [95% CI, 0.02-0.09] ln-mg/dL per allele, =0.001) but not the lowest SSB consumers (=0.84; =0.0005).
Conclusions: Our results identified genetic variants in the locus that may protect against SSB-associated reductions in HDL-C and other variants that may exacerbate SSB-associated increases in triglyceride concentrations. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005133, NCT00005121, NCT00005487, and NCT00000479.
Zeng W, Chu T, Fok B, Ho W, Chan J, Tomlinson B Dose Response. 2024; 22(4):15593258241303136.
PMID: 39583031 PMC: 11583496. DOI: 10.1177/15593258241303136.
Zhang M, Bai Y, Wang Y, Cui H, Zhang W, Zhang L Front Endocrinol (Lausanne). 2024; 15:1367229.
PMID: 38529389 PMC: 10961427. DOI: 10.3389/fendo.2024.1367229.
Rao G, Peng X, Li X, An K, He H, Fu X Front Med (Lausanne). 2023; 10:1294267.
PMID: 38089874 PMC: 10711211. DOI: 10.3389/fmed.2023.1294267.
Loika Y, Loiko E, Feng F, Stallard E, Yashin A, Arbeev K Aging (Albany NY). 2023; 15(9):3249-3272.
PMID: 37074818 PMC: 10449285. DOI: 10.18632/aging.204665.
The role of ChREBP in carbohydrate sensing and NAFLD development.
Regnier M, Carbinatti T, Parlati L, Benhamed F, Postic C Nat Rev Endocrinol. 2023; 19(6):336-349.
PMID: 37055547 DOI: 10.1038/s41574-023-00809-4.